F. Lhoas

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International Journal of Gynecologic Cancer.

A retrospective analysis of the results of p(65) + Be neutrontherapy for the treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Neuve. Part I: Survival and progression-free survival.

M. van Glabbeke, A. Wambersie, V. Remouchamps, 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

M. Piccart, K. Swenerton, B. Zee, 2000, Journal of the National Cancer Institute.

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.